Elgethun Capital Management Lineage Cell Therapeutics, Inc. Transaction History
Elgethun Capital Management
- $361 Million
- Q2 2024
A detailed history of Elgethun Capital Management transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Elgethun Capital Management holds 15,000 shares of LCTX stock, worth $13,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 15,000
-0.0%
Holding current value
$13,500
Previous $22,000
31.82%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$37.5 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.63 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.48 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.23 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $153M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...